Jael Birenberg has been with BioLineRx since June 2019, after spending ~18 years in different Regulatory Affairs positions within the Innovative R&D Division of Teva Pharmaceuticals. Ms. Birenberg led all FDA interactions and dossier preparations for the submission and review of the New Drug Application for BioLineRx’s innovative drug, Aphexda®, which was approved by the FDA in 2023, and also supports all other R&D activities at BioLineRx. In addition to her regulatory affairs responsibilities, Jael manages the Quality Assurance and Pharmacovigilance teams. Ms. Birenberg received her B.Sc. in Chemistry and M.Sc. in Organic Medicinal Chemistry, both from Bar-Ilan University in Israel.